“The strength of bisantrene’s performance with doxorubicin, a standard of care chemotherapy drug, is particularly exciting as it informs our clinical development plans and bolsters confidence that combining other cancer drugs with bisantrene will produce positive results for patients. We look forward to formally releasing this comprehensive set of cell screening data in upcoming peer-reviewed publications.”
Moving forward, RAC plans to refine drug dosages and combinations in more preclinical studies to identify optimal clinical treatment options for bisantrene. Further research will be conducted to investigate the molecular mechanisms behind the enhanced cancer cell killing when using doxorubicin and other drugs together. The completed data package will be published in a reputable peer-reviewed journal. Additionally, discussions with key opinion leaders will explore clinical trials combining bisantrene with doxorubicin to enhance outcomes for cancer patients.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)